Bertrand Anz Selected Research

Disease Progression

1/2022

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bertrand Anz Research Topics

Disease

4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 01/2019
2	Multiple Myeloma 01/2022 - 12/2020
1	Hypertension (High Blood Pressure) 01/2022
1	Disease Progression 01/2022
1	Residual Neoplasm 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Sudden Death 01/2019
1	Neuroendocrine Carcinoma 01/2019
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2017

Drug/Important Bio-Agent (IBA)

4	ibrutinibIBA 01/2022 - 01/2019
4	Chlorambucil (Leukeran)FDA Link 01/2022 - 01/2019
4	obinutuzumabIBA 01/2022 - 01/2019
2	pomalidomideIBA 01/2022 - 12/2020
2	daratumumabIBA 01/2022 - 12/2020
2	Lenalidomide (CC 5013)FDA Link 01/2022 - 12/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 12/2020
1	Estrogen ReceptorsIBA 01/2020
1	Hormones (Hormone)IBA 01/2020
1	Everolimus FDA Link 01/2020
1	Azacitidine (5 Azacytidine)FDA Link 05/2017
1	SB939 compoundIBA 05/2017

Therapy/Procedure

5	Therapeutics 01/2022 - 05/2017
1	Drug Therapy (Chemotherapy) 01/2019